WO2019058395A1 - Stable pharmaceutical compositions of dalfampridine - Google Patents
Stable pharmaceutical compositions of dalfampridine Download PDFInfo
- Publication number
- WO2019058395A1 WO2019058395A1 PCT/IN2018/050617 IN2018050617W WO2019058395A1 WO 2019058395 A1 WO2019058395 A1 WO 2019058395A1 IN 2018050617 W IN2018050617 W IN 2018050617W WO 2019058395 A1 WO2019058395 A1 WO 2019058395A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dalfampridine
- pharmaceutical composition
- composition
- cellulosic
- stable pharmaceutical
- Prior art date
Links
- 229960004979 fampridine Drugs 0.000 title claims abstract description 90
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical group NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 title claims abstract description 75
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 85
- 239000003085 diluting agent Substances 0.000 claims abstract description 37
- 238000013265 extended release Methods 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 229920000642 polymer Polymers 0.000 claims abstract description 16
- 238000009472 formulation Methods 0.000 claims description 43
- 239000012535 impurity Substances 0.000 claims description 35
- -1 glycowax Substances 0.000 claims description 25
- 239000002552 dosage form Substances 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 235000012211 aluminium silicate Nutrition 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 229940049654 glyceryl behenate Drugs 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 229920000569 Gum karaya Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical class COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 241000934878 Sterculia Species 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 229940023476 agar Drugs 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 2
- 229940006984 ampyra Drugs 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims description 2
- 229940082483 carnauba wax Drugs 0.000 claims description 2
- 235000013869 carnauba wax Nutrition 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229920000591 gum Polymers 0.000 claims description 2
- 235000010494 karaya gum Nutrition 0.000 claims description 2
- 239000000231 karaya gum Substances 0.000 claims description 2
- 229940039371 karaya gum Drugs 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 238000005461 lubrication Methods 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 150000004804 polysaccharides Chemical class 0.000 claims description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- 150000003445 sucroses Chemical class 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- 229940116362 tragacanth Drugs 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 208000012902 Nervous system disease Diseases 0.000 abstract description 3
- 208000025966 Neurological disease Diseases 0.000 abstract description 3
- 238000003860 storage Methods 0.000 description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 18
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000008213 purified water Substances 0.000 description 10
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 9
- LUTPBKQQLZGLPQ-UHFFFAOYSA-N n,n'-dipyridin-4-ylmethanediamine Chemical compound C=1C=NC=CC=1NCNC1=CC=NC=C1 LUTPBKQQLZGLPQ-UHFFFAOYSA-N 0.000 description 9
- 239000006186 oral dosage form Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 229960001021 lactose monohydrate Drugs 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940075065 polyvinyl acetate Drugs 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to stable extended release pharmaceutical compositions of Dalfampridine or salts thereof.
- the invention also relates to processes for the preparation of such compositions and use thereof for treatment of symptoms of multiple sclerosis (MS) and other neurological disorders.
- MS multiple sclerosis
- Dalfampridine also named as 4-aminopyridine, 4-AP, or fampridine
- 4-AP is an organic compound with the chemical formula C5H4N— NH2. It is used as a research tool, in characterizing subtypes of the potassium channel. It has also been used as a drug, to manage some of the symptoms of multiple sclerosis (MS), and is indicated for symptomatic improvement of walking in adults with several variations of the disease.
- MS multiple sclerosis
- the approved drug product in the United States, AMPYRA ® is an extended release tablet designed for twice-daily oral administration.
- Each tablet contains 10 mg active pharmaceutical ingredient which is Dalfampridine and comprises a rate-controlling polymeric matrix comprising of a hydrogel matrix, such as hydroxypropyl methylcellulose, which, when wet, swells to form a hydrogel thus the rate of release of Dalfampridine from the dosage formulation is sustained both by diffusion from the swollen tablet mass and by erosion of the tablet surface over time.
- the rate of release of Dalfampridine may be controlled both by the amount of polymer per tablet and by the inherent viscosities of the polymers used.
- MS Multiple Sclerosis
- CNS central nervous system
- Dalfampridine is known in the art for its potency in improving walking capacity in patients with multiple sclerosis.
- compositions comprising Dalfampridine have been reported to exhibit substantial degradation upon storage. It is believed that the drug reacts with some of the excipients present in the formulation leading to increase in the level of the impurities as well as formation of unidentified impurities during storage.
- US20170071923A1 provides a sustained release oral dosage form containing Dalfampridine that can be administered once daily.
- the dosage form includes Dalfampridine as the active pharmaceutical ingredient and the excipients comprising osmotic agents in a tablet core.
- WO2017058869A1 discloses sustained release 4-aminopyridine tablets, which include a core and a coating.
- the sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
- CN106551914A relates to a sustained release tablet comprising a Dalfampridine-containing tablet core, wherein the Dalfampridine-containing tablet core comprises of an adhesive agent, which results in a simple formulation with uniform drug content.
- An object of the present invention is to provide stable extended release pharmaceutical dosage forms comprising a therapeutically effective amount of Dalfampridine and exhibiting improved impurity profile upon storage.
- Another object of the present invention is to provide stable extended release pharmaceutical dosage forms, comprising a therapeutically effective amount of Dalfampridine, free of cellulosic diluents; and exhibiting improved impurity profile upon storage.
- Yet another object of the invention is to provide stable extended release pharmaceutical dosage forms, free of cellulosic diluents, and comprising a therapeutically effective amount of Dalfampridine, atleast one rate-controlling polymer, atleast one non-cellulosic diluent, and optionally one or more pharmaceutically acceptable excipients; and exhibiting improved impurity profile upon storage.
- Another object of the invention is to provide stable extended release pharmaceutical dosage forms, free of cellulosic diluents, and comprising a therapeutically effective amount of Dalfampridine, atleast one rate-controlling polymer, atleast one non-cellulosic diluent, and optionally one or more pharmaceutically acceptable excipients, characterized in that the extended release pharmaceutical compositions of the present invention are bioequivalent to the marketed formulation and exhibit improved impurity profile upon storage.
- another object of the invention is to provide stable extended release pharmaceutical dosage forms, free of cellulosic diluents, and comprising a therapeutically effective amount of Dalfampridine, atleast one rate-controlling polymer, atleast one non-cellulosic diluent, and optionally one or more pharmaceutically acceptable excipients, wherein about 20% to about 40% of said Dalfampridine is released after 2 hours; from about 45% to about 65% of said Dalfampridine is released after 8 hours; not less than about 70% of said Dalfampridine is released after 24 hours.
- Yet another object of the invention is to provide a simple and cost-effective method for preparation of stable extended release pharmaceutical dosage forms comprising a therapeutically effective amount of Dalfampridine.
- the present invention provides to stable extended release pharmaceutical dosage forms comprising a therapeutically effective amount of Dalfampridine and methods of preparing the same.
- Dalfampridine used throughout the specification refers to Dalfampridine, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof.
- the pharmaceutical compositions of the present invention comprise the Dalfampridine in an amount equivalent to 0.5 to 20 mg, preferably 5 to 15 mg of Dalfampridine.
- stable refers to physical stability and/or chemical stability of the active agent in a pharmaceutical composition, wherein changes in the drug assay values and/or impurities content are less than about 10%, during stability study storage of the composition at 25° C. and 60% relative humidity (RH), or 30° C. and 65% RH, or 40° C. and 75% RH, for durations such as 3, 6, 12, 18, or 24 months.
- Extended release as used herein in relation to the dosage form means which is not immediate release and is taken to encompass controlled release, prolonged release, timed release, retarded release, sustained release and delayed release. Extended release can be used interchangeably with prolonged release, programmed release, timed release, sustained release, controlled release and other such dosage forms.
- the "dosage form” include but is not limited to tablets, pellets, beads, granules, capsules, microcapsules and tablets in capsules.
- the term "Therapeutically effective amount” means that the amount of active agent, which halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition. A person skilled in the art can easily determine such an amount by routine experimentation and with an undue burden.
- Dalfampridine is believed to react with cellulosic diluents, which jeopardizes the stability of the composition and leads to increased formation of impurities; thus by avoiding the use of cellulosic diluents, the present invention provides an improved product with better stability and release profile.
- An embodiment of the present invention provides stable extended release pharmaceutical dosage forms, comprising a therapeutically effective amount of Dalfampridine, free of cellulosic diluents; and exhibiting improved impurity profile upon storage.
- a further embodiment of the present invention provides stable extended release pharmaceutical dosage forms, comprising a therapeutically effective amount of Dalfampridine, free of cellulosic diluents; which upon storage exhibit an improved impurity profile compared to a cellulosic diluent containing Dalfampridine composition.
- Another embodiment of the present invention provides stable extended release pharmaceutical dosage forms, comprising a therapeutically effective amount of Dalfampridine, atleast one rate- controlling polymer, atleast one non-cellulosic diluent, and optionally one or more pharmaceutically acceptable excipients, and exhibiting improved impurity profile upon storage.
- the rate-controlling polymers suitable for use in the present invention may include one or more of hydrophilic and hydrophobic polymers or mixtures thereof.
- Suitable hydrophilic polymers may include one or more of hydroxypropylcellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, cellulosic derivatives, vinyl acetate copolymers, polyethylene oxide, methacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers and derivatives, Eudragit RS, Eudragit RL, xanthan gum, karaya gum, locust bean gum, guar gum, gelan gum, gum arabic, tragacanth, carrageenan, pectin, carboxymethyl cellulose, agar, alginic acid, sodium alginate, polyvinylpyrrolidine, and mixtures thereof.
- the preferred hydrophilic polymer is hydroxypropyl methylcellulose or any commercially available grade thereof such as Methocel.
- Suitable hydrophobic polymers include one or more of ethyl cellulose, glycerol palmitostearate, beeswax, glycowax, carnaubawax, hydrogenated vegetable oil, glycerol monostearate, stearylalcohol, glyceryl behenate, polyanhydrides, methyl acrylates and the like.
- the rate-controlling polymers are present in the formulations of the present invention in an amount ranging from about 5 to about 90 wt. %; preferably from about 20 to about 75 wt.%.
- Suitable non-cellulosic diluent may include, but are not limited to one or more of dibasic calcium hydrogen phosphate, tricalcium phosphate, anhydrous calcium phosphate, magnesium aluminium silicates, Sucrose derivatives, Polysaccharides, lactose and mannitol and mixtures thereof.
- the preferred diluent is dibasic calcium phosphate.
- the non-cellulosic diluents are present in the formulations of the present invention in an amount ranging from about 20 to about 60 wt. %; preferably from about 30 to about 50 wt.%.
- “Optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
- “optionally pharmaceutical excipients” indicates that a formulation so described may or may not include pharmaceutical excipients other than those specifically stated to be present, and that the formulation so described includes instances in which the optional excipients are present and instances in which they are not.
- the pharmaceutical dosage forms of the present invention may comprise additional pharmaceutically acceptable excipients selected from the group consisting lubricants, disintegrants, binders, glidants, colorants, sweeteners, plasticizers and the like.
- Suitable lubricants and glidants may include one or more of talc, metallic stearates such as magnesium stearate, calcium stearate, zinc stearate; colloidal silicon dioxide, finely divided silicon dioxide, stearic acid, hydrogenated vegetable oil, glyceryl palmitostearate, glyceryl monostearate, glyceryl behenate, polyethylene glycols, powdered cellulose, starch, sodium stearyl fumarate, sodium benzoate, mineral oil, magnesium trisilicate, kaolin; and the like.
- Preferred lubricants for use in the present invention are talc and magnesium stearate. The amount of lubricant in the composition ranges from 0.1% to 3% w/w of composition.
- Suitable disintegrants may include, but not limited to one or more of croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and the like.
- Suitable binders may include one or more of hydroxyethyl cellulose, hydroxypropyl cellulose, carbomers, dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinyl pyrrolidone (e.g. Povidone K 30), pregelatinized starch, sodium alginate, gums, synthetic resins and the like.
- Preferred binder for use in the present invention is polyvinyl pyrrolidone.
- Suitable plasticizers may include, but not limited to one or more of polyols such as glycerol, propylene glycol, polyethylene glycol (PEG), urea, or other known plasticizers such as triethyl citrate, dibutyl+ or dimethyl phthalate or water.
- polyols such as glycerol, propylene glycol, polyethylene glycol (PEG), urea, or other known plasticizers such as triethyl citrate, dibutyl+ or dimethyl phthalate or water.
- Another embodiment of the present invention provides a simple and cost-effective method for preparation of stable extended release pharmaceutical dosage forms comprising a therapeutically effective amount of Dalfampridine.
- compositions of the present invention can be prepared by various methods known in the art such as by dry granulation, wet granulation, melt granulation, direct compression, double compression, extrusion spheronization, layering and the like.
- Extended release pharmaceutical dosage forms according to the present invention are manufactured preferably as per the following procedure: i) Blending the active agent, rate-controlling polymer(s), non-cellulosic diluent (s) and one or more pharmaceutically acceptable excipient(s),
- the pharmaceutical dosage forms of the invention may further be coated.
- the coating may be a functional or non-functional coating.
- the preferred coating of this invention is comprised of a commercial film-coating product designed for aqueous film coating containing the water-soluble, film-forming resin, such a product is commercially available under the trade name Opadry White. These coating comprises one or more excipients selected from the group comprising coating agents, opacifiers, fillers, polishing agents, colouring agents, anti tacking agents and the like.
- Present invention further provides a method of treating multiple sclerosis or a symptom thereof in a subject in need thereof, the method comprises administering an extended release pharmaceutical composition comprising Dalfampridine or salts thereof as substantially described herein before.
- Example 1 Extended release tablets of Dalfampridine by direct compression method
- Example 2 Extended release composition of Dalfampridine by direct compression method
- Example 3 Extended release composition of Dalfampridine by direct compression method
- Example 4 Extended release composition of Dalfampridine by dry granulation method
- Example 5 Extended release composition of Dalfampridine by wet granulation method
- the dry mix material was granulated using a binder solution and dried.
- the dry granules were then lubricated and the lubricated granules were then compressed into suitable solid oral dosage forms.
- the solid oral dosage forms were finally coated with Opadry dispersion in purified water.
- Example 6 Stability Data and Comparative analysis: 6.1: Stability Data of Example 1
- the amount of the impurity formed during the storage period was measured in the formulation during the storage period of 3 months at interval of 1 , 2 and 3 months, which conclusively indicates that the formulation of the invention is stable under stress conditions.
- the amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
- the amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
- a comparative formulation was prepared with the same excipients in similar quantities as used in Example 1 ; except for the diluents used in the formulations.
- a cellulosic diluent for example, microcrystalline cellulose was used instead of non-cellulosic diluents.
- the amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
- Example 7 Stability Data of present composition in other packaging's and comparison with test formulations
- the amount of the impurity formed during the storage period was measured in the formulation after the storage period of 3 and 6 months, which conclusively indicates that the formulation of the invention is stable under stress conditions.
- the amount of impurity refers to the percent by weight of Dalfampridine or salts thereof. 7.2: 6 Months Stability Data at 40°C/75%RH
- the amount of the impurity formed during the storage period was measured in the formulation during the storage period of 6 months at interval of 1, 2, 3 and 6 months, which conclusively indicates that the formulation of the invention is stable under stress conditions.
- the amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
- the comparative formulation were prepared with the same excipients in similar quantities as used in formulation of Example 7.1; except for the diluents used in the formulations.
- a cellulosic diluent for example, microcrystalline cellulose was used instead of non- cellulosic diluents.
- the amount of the impurity formed during the storage period was measured in the formulation after the end of the storage period of 3 and 6 months respectively, which conclusively indicates that the test formulation is not stable under stress conditions.
- the amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
- the comparative formulation were prepared with the same excipients in similar quantities as used in formulation of Example 7.2; except for the diluents used in the formulations.
- a cellulosic diluent for example, microcrystalline cellulose was used instead of non- cellulosic diluents.
- the stability study of formulation with batch size of 15000 tablets were conducted at 40 °C. /75% RH over the period of 6 months.
- the amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
- test formulation prepared as per present invention were found to be more stable with lesser impurities content during accelerated stability studies when compared to the cellulose containing formulations.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to stable extended release pharmaceutical compositions of Dalfampridine or salts thereof; free of cellulosic diluents. The invention typically relates to processes for the preparation of stable extended release pharmaceutical compositions of Dalfampridine comprising atleast one rate controlling polymer and atleast one non-cellulosic diluent; and use of such compositions for treatment of symptoms of multiple sclerosis (MS) and other neurological disorders.
Description
FIELD OF THE INVENTION
The present invention relates to stable extended release pharmaceutical compositions of Dalfampridine or salts thereof. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of symptoms of multiple sclerosis (MS) and other neurological disorders.
BACKGROUND OF THE INVENTION
Dalfampridine, also named as 4-aminopyridine, 4-AP, or fampridine, is an organic compound with the chemical formula C5H4N— NH2. It is used as a research tool, in characterizing subtypes of the potassium channel. It has also been used as a drug, to manage some of the symptoms of multiple sclerosis (MS), and is indicated for symptomatic improvement of walking in adults with several variations of the disease.
The approved drug product in the United States, AMPYRA®, is an extended release tablet designed for twice-daily oral administration. Each tablet contains 10 mg active pharmaceutical ingredient which is Dalfampridine and comprises a rate-controlling polymeric matrix comprising of a hydrogel matrix, such as hydroxypropyl methylcellulose, which, when wet, swells to form a hydrogel thus the rate of release of Dalfampridine from the dosage formulation is sustained both by diffusion from the swollen tablet mass and by erosion of the tablet surface over time. The rate of release of Dalfampridine may be controlled both by the amount of polymer per tablet and by the inherent viscosities of the polymers used.
Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS) with both inflammatory and degenerative components. It is the most common neurologic, disabling disease in young adults (Frohman, 2003, The Medical Clinics of North America, 87(4): 867-897, viii-ix). Permanent neurological dysfunction can result from incomplete recovery from acute relapses or as a consequence of slow progression of disability. Overall, about 75-85% of MS individuals have some degree of ambulatory impairment and over half need assistance both indoors and outdoors (Kraft et al., 1986, Arch Phys Med Rehabil 67: 164-168; Weinshenker et al, 1989,
Brain 112: 133-146). More than one third do not retain the ability to walk 20 years after the diagnosis (Schapiro, 1991, A Rehabilitation Approach to Management, Demos, New York).
Dalfampridine is known in the art for its potency in improving walking capacity in patients with multiple sclerosis. However, compositions comprising Dalfampridine have been reported to exhibit substantial degradation upon storage. It is believed that the drug reacts with some of the excipients present in the formulation leading to increase in the level of the impurities as well as formation of unidentified impurities during storage.
US20170071923A1 provides a sustained release oral dosage form containing Dalfampridine that can be administered once daily. The dosage form includes Dalfampridine as the active pharmaceutical ingredient and the excipients comprising osmotic agents in a tablet core.
WO2017058869A1 discloses sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
CN106551914A relates to a sustained release tablet comprising a Dalfampridine-containing tablet core, wherein the Dalfampridine-containing tablet core comprises of an adhesive agent, which results in a simple formulation with uniform drug content.
The prior art references emphasize on the development pharmaceutical compositions of Dalfampridine with improved release profile suitable for once daily administration, however, there is no disclosure or teaching/suggestion in the art about how to develop commercially viable formulations of Dalfampridine with improved stability using non-cellulosic diluents.
Therefore, it would be desirable to develop new pharmaceutical compositions comprising Dalfampridine that are more stable against degradation over storage period and simultaneously, provide desired extended release of the drug Surprisingly, it has been found that stable extended release dosage form of Dalfampridine can be prepared using non-cellulosic diluents, that upon storage, exhibits an impurity profile that is within desired levels and at the same time is bioequivalent to the marketed formulation.
SUMMARY OF THE INVENTION
An object of the present invention is to provide stable extended release pharmaceutical dosage forms comprising a therapeutically effective amount of Dalfampridine and exhibiting improved impurity profile upon storage.
Another object of the present invention is to provide stable extended release pharmaceutical dosage forms, comprising a therapeutically effective amount of Dalfampridine, free of cellulosic diluents; and exhibiting improved impurity profile upon storage.
Yet another object of the invention is to provide stable extended release pharmaceutical dosage forms, free of cellulosic diluents, and comprising a therapeutically effective amount of Dalfampridine, atleast one rate-controlling polymer, atleast one non-cellulosic diluent, and optionally one or more pharmaceutically acceptable excipients; and exhibiting improved impurity profile upon storage.
Another object of the invention is to provide stable extended release pharmaceutical dosage forms, free of cellulosic diluents, and comprising a therapeutically effective amount of Dalfampridine, atleast one rate-controlling polymer, atleast one non-cellulosic diluent, and optionally one or more pharmaceutically acceptable excipients, characterized in that the extended release pharmaceutical compositions of the present invention are bioequivalent to the marketed formulation and exhibit improved impurity profile upon storage. Further, another object of the invention is to provide stable extended release pharmaceutical dosage forms, free of cellulosic diluents, and comprising a therapeutically effective amount of Dalfampridine, atleast one rate-controlling polymer, atleast one non-cellulosic diluent, and optionally one or more pharmaceutically acceptable excipients, wherein about 20% to about 40% of said Dalfampridine is released after 2 hours; from about 45% to about 65% of said Dalfampridine is released after 8 hours; not less than about 70% of said Dalfampridine is released after 24 hours.
Yet another object of the invention is to provide a simple and cost-effective method for preparation of stable extended release pharmaceutical dosage forms comprising a therapeutically effective amount of Dalfampridine.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides to stable extended release pharmaceutical dosage forms comprising a therapeutically effective amount of Dalfampridine and methods of preparing the same.
The term "Dalfampridine" used throughout the specification refers to Dalfampridine, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof.
Typically, the pharmaceutical compositions of the present invention comprise the Dalfampridine in an amount equivalent to 0.5 to 20 mg, preferably 5 to 15 mg of Dalfampridine. The term "stable" as used herein refers to physical stability and/or chemical stability of the active agent in a pharmaceutical composition, wherein changes in the drug assay values and/or impurities content are less than about 10%, during stability study storage of the composition at 25° C. and 60% relative humidity (RH), or 30° C. and 65% RH, or 40° C. and 75% RH, for durations such as 3, 6, 12, 18, or 24 months. The term "extended release" as used herein in relation to the dosage form means which is not immediate release and is taken to encompass controlled release, prolonged release, timed release, retarded release, sustained release and delayed release. Extended release can be used interchangeably with prolonged release, programmed release, timed release, sustained release, controlled release and other such dosage forms.
The "dosage form" according to the present invention include but is not limited to tablets, pellets, beads, granules, capsules, microcapsules and tablets in capsules.
The term "Therapeutically effective amount" means that the amount of active agent, which halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition. A person skilled in the art can easily determine such an amount by routine experimentation and with an undue burden.
Dalfampridine is believed to react with cellulosic diluents, which jeopardizes the stability of the composition and leads to increased formation of impurities; thus by avoiding the use of cellulosic diluents, the present invention provides an improved product with better stability and release profile. An embodiment of the present invention provides stable extended release pharmaceutical dosage forms, comprising a therapeutically effective amount of Dalfampridine, free of cellulosic diluents; and exhibiting improved impurity profile upon storage.
A further embodiment of the present invention provides stable extended release pharmaceutical dosage forms, comprising a therapeutically effective amount of Dalfampridine, free of cellulosic diluents; which upon storage exhibit an improved impurity profile compared to a cellulosic diluent containing Dalfampridine composition.
Another embodiment of the present invention provides stable extended release pharmaceutical dosage forms, comprising a therapeutically effective amount of Dalfampridine, atleast one rate- controlling polymer, atleast one non-cellulosic diluent, and optionally one or more pharmaceutically acceptable excipients, and exhibiting improved impurity profile upon storage.
Accordingly, the rate-controlling polymers suitable for use in the present invention may include one or more of hydrophilic and hydrophobic polymers or mixtures thereof.
Suitable hydrophilic polymers may include one or more of hydroxypropylcellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, cellulosic derivatives, vinyl acetate copolymers, polyethylene oxide, methacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers and derivatives, Eudragit RS, Eudragit RL, xanthan gum, karaya gum, locust bean gum, guar gum, gelan gum, gum arabic, tragacanth, carrageenan, pectin, carboxymethyl cellulose, agar, alginic acid, sodium alginate, polyvinylpyrrolidine, and
mixtures thereof. The preferred hydrophilic polymer is hydroxypropyl methylcellulose or any commercially available grade thereof such as Methocel.
Suitable hydrophobic polymers include one or more of ethyl cellulose, glycerol palmitostearate, beeswax, glycowax, carnaubawax, hydrogenated vegetable oil, glycerol monostearate, stearylalcohol, glyceryl behenate, polyanhydrides, methyl acrylates and the like.
Typically, the rate-controlling polymers are present in the formulations of the present invention in an amount ranging from about 5 to about 90 wt. %; preferably from about 20 to about 75 wt.%.
Suitable non-cellulosic diluent may include, but are not limited to one or more of dibasic calcium hydrogen phosphate, tricalcium phosphate, anhydrous calcium phosphate, magnesium aluminium silicates, Sucrose derivatives, Polysaccharides, lactose and mannitol and mixtures thereof. The preferred diluent is dibasic calcium phosphate.
Typically, the non-cellulosic diluents are present in the formulations of the present invention in an amount ranging from about 20 to about 60 wt. %; preferably from about 30 to about 50 wt.%.
"Optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally pharmaceutical excipients" indicates that a formulation so described may or may not include pharmaceutical excipients other than those specifically stated to be present, and that the formulation so described includes instances in which the optional excipients are present and instances in which they are not.
The pharmaceutical dosage forms of the present invention may comprise additional pharmaceutically acceptable excipients selected from the group consisting lubricants, disintegrants, binders, glidants, colorants, sweeteners, plasticizers and the like. Suitable lubricants and glidants may include one or more of talc, metallic stearates such as magnesium stearate, calcium stearate, zinc stearate; colloidal silicon dioxide, finely divided silicon dioxide, stearic acid, hydrogenated vegetable oil, glyceryl palmitostearate, glyceryl monostearate,
glyceryl behenate, polyethylene glycols, powdered cellulose, starch, sodium stearyl fumarate, sodium benzoate, mineral oil, magnesium trisilicate, kaolin; and the like. Preferred lubricants for use in the present invention are talc and magnesium stearate. The amount of lubricant in the composition ranges from 0.1% to 3% w/w of composition.
Suitable disintegrants may include, but not limited to one or more of croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and the like. Suitable binders may include one or more of hydroxyethyl cellulose, hydroxypropyl cellulose, carbomers, dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinyl pyrrolidone (e.g. Povidone K 30), pregelatinized starch, sodium alginate, gums, synthetic resins and the like. Preferred binder for use in the present invention is polyvinyl pyrrolidone. Suitable plasticizers may include, but not limited to one or more of polyols such as glycerol, propylene glycol, polyethylene glycol (PEG), urea, or other known plasticizers such as triethyl citrate, dibutyl+ or dimethyl phthalate or water.
Another embodiment of the present invention provides a simple and cost-effective method for preparation of stable extended release pharmaceutical dosage forms comprising a therapeutically effective amount of Dalfampridine.
The pharmaceutical compositions of the present invention can be prepared by various methods known in the art such as by dry granulation, wet granulation, melt granulation, direct compression, double compression, extrusion spheronization, layering and the like.
Extended release pharmaceutical dosage forms according to the present invention are manufactured preferably as per the following procedure: i) Blending the active agent, rate-controlling polymer(s), non-cellulosic diluent (s) and one or more pharmaceutically acceptable excipient(s),
ii) Subjecting the blend to lubrication,
iii) Compressing the lubricated blend into suitable dosage form.
The pharmaceutical dosage forms of the invention may further be coated. The coating may be a functional or non-functional coating. The preferred coating of this invention is comprised of a commercial film-coating product designed for aqueous film coating containing the water-soluble, film-forming resin, such a product is commercially available under the trade name Opadry White. These coating comprises one or more excipients selected from the group comprising coating agents, opacifiers, fillers, polishing agents, colouring agents, anti tacking agents and the like. Present invention further provides a method of treating multiple sclerosis or a symptom thereof in a subject in need thereof, the method comprises administering an extended release pharmaceutical composition comprising Dalfampridine or salts thereof as substantially described herein before.
The principles, preferred embodiments, and modes of operation of the present invention have been described in the foregoing specification. The invention which is intended to be protected herein, however, is not to be construed limited to the particular forms disclosed, since these are to be regarded as illustrative rather than restrictive. Variations or changes may be made by those skilled in the art, without departing from the spirit of the invention. The following examples further illustrate the invention but should not be construed as in any way limiting its scope. In particular, the processing conditions are merely exemplary and can be readily varied by one of ordinary skill in the art.
Examples: Example 1: Extended release tablets of Dalfampridine by direct compression method
Component % w/w
Dalfampridine 2.5
Hydroxypropyl methyl cellulose 60.0
Calcium hydrogen phosphate 36.5
Colloidal silicon dioxide 0.4
Magnesium Stearate 0.2
Opadry 0.4
Purified water Q.S.
Procedure:
Mixture of Dalfampridine, hydroxypropyl methyl cellulose, calcium hydrogen phosphate and colloidal silicon dioxidewas lubricated with magnesium stearate. The lubricated blend was then compressed into tablets. The tablets were finally coated with Opadry dispersion in purified water.
Example 2: Extended release composition of Dalfampridine by direct compression method
Component % w/w
Dalfampridine 2.5
Hydroxyethyl cellulose 46.0
Lactose monohydrate 49.9
Colloidal silicon dioxide 0.4
Magnesium Stearate 0.8
Opadry 0.4
Purified water Q.S.
Procedure:
Mixture of Dalfampridine, hydroxyethyl cellulose, lactose monohydrate and colloidal silicon dioxide was lubricated with magnesium stearate. The lubricated blend was then compressed into suitable solid oral dosage forms. The solid oral dosage forms were finally coated with Opadry dispersion in purified water.
Example 3: Extended release composition of Dalfampridine by direct compression method
Component % w/w
Dalfampridine 2.5
Polyvinyl acetate 38.0
Povidone 21.4
Lactose monohydrate 36.5
Colloidal silicon dioxide 0.4
Magnesium Stearate 0.8
Opadry 0.4
Purified water Q.S.
Procedure:
Mixture of Dalfampridine, polyvinyl acetate, povidone, lactose monohydrate and colloidal silicon dioxide was lubricated with magnesium stearate. The lubricated blend was then compressed into suitable solid oral dosage forms. The solid oral dosage forms were finally coated with Opadry dispersion in purified water.
Example 4: Extended release composition of Dalfampridine by dry granulation method
Component % w/w
Dalfampridine 2.5
Magnesium aluminometasilicate 4.8
Methyl cellulose 33.7
Lactose monohydrate 36.0
Colloidal silicon dioxide 0.4
Magnesium Stearate 0.8
Opadry 0.4
Purified water Q.S.
Procedure:
Mixture of Dalfampridine, magnesium aluminometasilicate, methyl cellulose, lactose monohydrate and colloidal silicon dioxide was granulated using a roller compactor and then lubricated with
magnesium stearate. The lubricated granules were then compressed into suitable solid oral dosage forms. The solid oral dosage forms were finally coated with Opadry dispersion in purified water.
Example 5: Extended release composition of Dalfampridine by wet granulation method
Component % w/w
Dalfampridine 2.5
Hydroxypropyl cellulose 63.5
Lactose monohydrate 32.4
Colloidal silicon dioxide 0.4
Magnesium Stearate 0.8
Opadry 0.4
Purified water Q.S.
Procedure:
The dry mix material was granulated using a binder solution and dried. The dry granules were then lubricated and the lubricated granules were then compressed into suitable solid oral dosage forms. The solid oral dosage forms were finally coated with Opadry dispersion in purified water.
Example 6: Stability Data and Comparative analysis: 6.1: Stability Data of Example 1
The stability study of formulation prepared as per Example 1 , was conducted at 40 °C. 115% RH over the period of 3 months.
The amount of the impurity formed during the storage period was measured in the formulation during the storage period of 3 months at interval of 1 , 2 and 3 months, which conclusively indicates that the formulation of the invention is stable under stress conditions.
Pack: HDPE Bottle with desiccant canister
Time in Months
Test Specification with limits
Initial 1
Related Dalfampridine N-Oxide - NMT 0.2% w/w ND ND ND ND
Substances 3-Amino pyridine - NMT 0.2% w/w ND ND ND ND
2-Amino pyridine - NMT 0.2% w/w ND ND ND ND
Hydroxy Dalfampridine - NMT 0.2% w/w ND ND 0.02 ND
N,N'-di (4-pyridinyl)methanediamine - NMT 2.0%
0.12 0.16 0.19 0.26 w/w
Unknown - NMT 0.2% w/w ND 0.06 0.04 0.05
Total - NMT 2.5% w/w 0.12 0.22 0.25 0.27
ND: Not Detected; NMT: Not More Than
Note: The amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
Pack: Blister pack
Time in Months
Test Specification with limits
Initial 1 2 3
Related Dalfampridine N-Oxide - NMT 0.2% w/w ND ND ND ND
Substances 3-Amino pyridine - NMT 0.2% w/w ND ND ND ND
2-Amino pyridine - NMT 0.2% w/w ND ND ND ND
Hydroxy Dalfampridine - NMT 0.2% w/w ND ND ND ND
N,N'-di (4-pyridinyl)methanediamine - NMT 2.0%
0.12 0.17 0.13 0.25 w/w
Unknown - NMT 0.2% w/w ND 0.05 0.13 0.06
Total - NMT 2.5% w/w 0.12 0.22 0.26 0.31
ND: Not Detected; NMT: Not More Than
Note: The amount of impurity refers to the percent by weight of Dalfampridine or salts thereof. 6.2: Stability Data of Comparative formulation to Example 1
A comparative formulation was prepared with the same excipients in similar quantities as used in Example 1 ; except for the diluents used in the formulations. In the comparative example, a cellulosic diluent, for example, microcrystalline cellulose was used instead of non-cellulosic diluents.
The accelerated stability study of this formulation was conducted at 40 UC. /75% RH over the period of 3 months.
The amount of the impurity formed during the storage period was measured in the formulation during the storage period of 3 months at interval of 1, 2 and 3 months, which conclusively indicates that the formulation is not stable under stress conditions. Pack: HDPE Bottle with desiccant canister
Time in Months
Test Specification with limits
Initial 1 2 3
Related Dalfampridine N-Oxide - NMT 0.2% w/w ND ND ND ND
Substances 3-Amino pyridine - NMT 0.2% w/w ND ND ND ND
2- Amino pyridine - NMT 0.2% w/w ND ND ND ND
Hydroxy Dalfampridine - NMT 0.2% w/w ND ND ND ND
N,N'-di (4-pyridinyl)methanediamine - NMT 2.0%
0.08 0.18 0.28 0.26 w/w
Unknown - NMT 0.2% w/w ND 0.46 1.96 2.24
Total - NMT 2.5% w/w 0.08 0.64 2.24 2.5
ND: Not Detected; NMT: Not More Than
Note: The amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
Example 7: Stability Data of present composition in other packaging's and comparison with test formulations
7.1: 6 Months Stability Data at 30°C/65%RH & 25°C/60%RH
The stability study of formulation with batch size of 10000 tablets were conducted at 30°C/65%RH & 25°C/60%RH over the period of 6 months.
The amount of the impurity formed during the storage period was measured in the formulation after the storage period of 3 and 6 months, which conclusively indicates that the formulation of the invention is stable under stress conditions.
Pack: Dessiflex Blister at 30°C/65%RH
Time in Months
Specification with limits
Initial 3 6
Related Dalfampridine N-Oxide - NMT 0.2% w/w ND ND ND
Substances 3-Amino pyridine - NMT 0.2% w/w ND ND ND
2-Amino pyridine - NMT 0.2% w/w ND ND ND
Hydroxy Dalfampridine - NMT 0.2% w/w ND ND ND
N,N'-di (4-pyridinyl)methanediamine - NMT 2.0%
0.19 0.2 0.11 w/w
Any individual unknown impurity - NMT 0.2% w/w 0.02 0.02 0.02
Total - NMT 2.5% w/w 0.25 0.27 0.14
ND: Not Detected; NMT: Not More Than
Pack: Dessiflex Blister at 25°C/60%RH
Time in Months
Test Specification with limits
Initial 3 6
Related Dalfampridine N-Oxide - NMT 0.2% w/w ND ND ND
Substances 3-Amino pyridine - NMT 0.2% w/w ND ND ND
2-Amino pyridine - NMT 0.2% w/w ND ND ND
Hydroxy Dalfampridine - NMT 0.2% w/w ND ND ND
N,N'-di (4-pyridinyl)methanediamine - NMT 2.0%
0.19 0.2 0.11 w/w
Any individual unknown impurity - NMT 0.2% w/w 0.02 0.02 0.02
Total - NMT 2.5% w/w 0.25 0.27 0.14
ND: Not Detected; NMT: Not More Than
Note: The amount of impurity refers to the percent by weight of Dalfampridine or salts thereof. 7.2: 6 Months Stability Data at 40°C/75%RH
The stability study of formulation with batch size of 10000 tablets were conducted at 40 UC. /75% RH over the period of 6 months.
The amount of the impurity formed during the storage period was measured in the formulation during the storage period of 6 months at interval of 1, 2, 3 and 6 months, which conclusively indicates that the formulation of the invention is stable under stress conditions.
Pack: Dessiflex Blister
Time in Months
Test Specification with limits
Initial 2 3 6
Related Dalfampridine N-Oxide - NMT 0.2% w/w ND ND ND ND
Substances 3-Amino pyridine - NMT 0.2% w/w ND ND ND ND
2-Amino pyridine - NMT 0.2% w/w ND ND ND ND
Hydroxy Dalfampridine - NMT 0.2% w/w ND ND 0.02 ND
N,N'-di (4-pyridinyl)methanediamine - NMT 2.0%
0.19 0.17 0.18 0.16 w/w
Any individual unknown impurity - NMT 0.2% w/w 0.02 0.02 0.02 0.06
Total - NMT 2.5% w/w 0.25 0.23 0.32 0.32
ND: Not Detected; NMT: Not More Than
Note: The amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
7.3: 6 Months Stability Data at 30°C/65%RH & 25°C/60%RH for test formulation with cellulose
The comparative formulation were prepared with the same excipients in similar quantities as used in formulation of Example 7.1; except for the diluents used in the formulations. In the comparative example, a cellulosic diluent, for example, microcrystalline cellulose was used instead of non- cellulosic diluents.
The accelerated stability study of test formulation with batch size of 15000 tablets were conducted at 30°C/65%RH & 25°C/60%RH over the period of 6 months.
The amount of the impurity formed during the storage period was measured in the formulation after the end of the storage period of 3 and 6 months respectively, which conclusively indicates that the test formulation is not stable under stress conditions.
Pack: Dessiflex Blister at 30°C/65%RH
Time in Months
Specification with limits
Initial 3 6
Related Dalfampridine N-Oxide - NMT 0.2% w/w ND ND ND
Substances 3-Amino pyridine - NMT 0.2% w/w ND ND ND
2-Amino pyridine - NMT 0.2% w/w ND ND ND
Hydroxy Dalfampridine - NMT 0.2% w/w ND ND ND
N,N'-di (4-pyridinyl)methanediamine - NMT 2.0%
0.13 0.21 0.13 w/w
Any individual unknown impurity - NMT 0.2% w/w 0.03 0.06 0.11
Total - NMT 2.5% w/w 0.20 0.75 0.81
ND: Not Detected; NMT: Not More Than
Pack: Dessiflex Blister at 25°C/60%RH
Time in Months
Test Specification with limits
Initial 3 6
Related Dalfampridine N-Oxide - NMT 0.2% w/w ND ND ND
Substances 3-Amino pyridine - NMT 0.2% w/w ND ND ND
2-Amino pyridine - NMT 0.2% w/w ND ND ND
Hydroxy Dalfampridine - NMT 0.2% w/w ND ND ND
N,N'-di (4-pyridinyl)methanediamine - NMT 2.0%
0.13 0.18 0.13 w/w
Any individual unknown impurity - NMT 0.2% w/w 0.03 0.05 0.09
Total - NMT 2.5% w/w 0.20 0.44 0.47
ND: Not Detected; NMT: Not More Than
Note: The amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
7.4: 6 Months Stability Data at 40°C/75%RH for test formulation with cellulose
The comparative formulation were prepared with the same excipients in similar quantities as used in formulation of Example 7.2; except for the diluents used in the formulations. In the comparative example, a cellulosic diluent, for example, microcrystalline cellulose was used instead of non- cellulosic diluents. The stability study of formulation with batch size of 15000 tablets were conducted at 40 °C. /75% RH over the period of 6 months.
The amount of the impurity formed during the storage period was measured in the formulation during the storage period of 6 months at interval of 1, 2, 3 and 6 months, which conclusively indicates that the test formulation is not stable under stress conditions.
Pack: Dessiflex Blister
Time in Months
Test Specification with limits
Initial 2 3 6
Related Dalfampridine N-Oxide - NMT 0.2% w/w ND ND ND ND
Substances 3-Amino pyridine - NMT 0.2% w/w ND ND ND ND
2-Amino pyridine - NMT 0.2% w/w ND ND ND ND
Hydroxy Dalfampridine - NMT 0.2% w/w ND ND 0.02 ND
N,N'-di (4-pyridinyl)methanediamine - NMT 2.0%
0.13 0.24 0.25 0.13 w/w
Any individual unknown impurity - NMT 0.2% w/w 0.03 0.17 0.23 0.35
Total - NMT 2.5% w/w 0.20 1.44 1.8 2.97
ND: Not Detected; NMT: Not More Than
Note: The amount of impurity refers to the percent by weight of Dalfampridine or salts thereof.
Conclusively the inventor concluded that the test formulation prepared as per present invention were found to be more stable with lesser impurities content during accelerated stability studies when compared to the cellulose containing formulations.
Claims
1. A stable extended release pharmaceutical composition comprising Dalfampridine or salts thereof, wherein the composition is free of cellulosic diluents.
2. A stable extended release pharmaceutical composition of Dalfampridine characterized in which the composition is free of cellulosic diluents wherein the composition comprises: a. a therapeutically effective amount of Dalfampridine or its pharmaceutically acceptable salts ;
b. at least one rate-controlling polymer; and
c. at least one non-cellulosic diluent.
3. The stable pharmaceutical composition as claimed in claim 1 or 2, wherein the composition comprises at least one rate-controlling polymer, at least one non-cellulosic diluent and one or more pharmaceutically acceptable excipients.
4. The stable pharmaceutical composition as claimed in claim 1 or 2, wherein the composition comprises 0.5 to 20 mg of Dalfampridine or salts thereof, at least one rate-controlling polymer ranging from about 5 to about 90 wt. %, at least one non-cellulosic diluent ranging from about 20 to 60 wt. %, and one or more pharmaceutically acceptable excipients.
5. The stable pharmaceutical composition as claimed in claim 4, wherein the composition is free of any cellulosic diluents.
6. The stable pharmaceutical composition as claimed in claims 2 and 3, wherein the rate-controlling polymer is one or more of a hydrophilic polymer, a hydrophobic polymer or a combination thereof.
7. The stable pharmaceutical composition as claimed in claim 6, wherein the hydrophilic polymer comprises one or more of hydroxypropylcellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, cellulosic derivatives, vinyl acetate copolymers, polyethylene oxide, methacrylic acid copolymers, maleic anhydride/methyl vinyl
ether copolymers and derivatives, xanthan gum, karaya gum, locust bean gum, guar gum, gelan gum, gum arabic, tragacanth, carrageenan, pectin, carboxymethyl cellulose, agar, alginic acid, sodium alginate, polyvinylpyrrolidine, and mixtures thereof.
8. The stable pharmaceutical composition as claimed in claim 6, wherein the hydrophobic polymer comprises one or more of ethyl cellulose, glycerol palmitostearate, beeswax, glycowax, carnaubawax, hydrogenated vegetable oil, glycerol monostearate, stearylalcohol, glyceryl behenate, polyanhydrides, methyl acrylates, and mixtures thereof.
9. The stable pharmaceutical composition as claimed in claim 2 or 3, wherein the non-cellulosic diluent is selected from the group consisting of dibasic calcium hydrogen phosphate, tricalcium phosphate, anhydrous calcium phosphate, magnesium aluminium silicates, sucrose derivatives, Polysaccharides, lactose, mannitol and mixtures thereof.
10. The stable pharmaceutical composition as claimed in claims 2 or 3, wherein the pharmaceutically acceptable excipients are selected from binders, lubricants, disintegrants, glidants or combinations thereof.
11. The stable pharmaceutical composition as claimed in claims 1 or 2, wherein the composition further comprises functional or non-functional coating.
12. The stable pharmaceutical composition as claimed in claims 1 and 2, wherein the composition exhibits no significant difference in rate and/or extent of absorption of Dalfampridine as compared to extended release formulation commercially marketed under the trade name AMPYRA®.
13. The stable pharmaceutical composition as claimed in any of the preceding claims, wherein the composition contains less than 1.5% of total impurities by weight of Dalfampridine or salts thereof, preferably less than 0.5% of total impurities by weight of Dalfampridine or salts thereof, when stored at 40 °C./75% RH for 6 months.
14. The stable pharmaceutical composition as claimed in any of the preceding claims wherein the composition contains any single impurity not more than 0.5% by weight of Dalfampridine or salts thereof, when stored at 40 °C./75% RH for 6 months.
15. The stable pharmaceutical composition as claimed in claim 1, wherein the composition is prepare by a process comprising the steps of: i. blending Dalfampridine or its pharmaceutically acceptable salt, at least a rate controlling polymer, at least a non-cellulosic polymer and one or more pharmaceutically acceptable excipients;
ii. subjecting the blend from step i) to lubrication; and
iii. compressing the lubricated blend from step ii) into suitable dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18858773.7A EP3687539A4 (en) | 2017-09-25 | 2018-09-21 | Stable pharmaceutical compositions of dalfampridine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741033883 | 2017-09-25 | ||
| IN201741033883 | 2017-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019058395A1 true WO2019058395A1 (en) | 2019-03-28 |
Family
ID=65811198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2018/050617 WO2019058395A1 (en) | 2017-09-25 | 2018-09-21 | Stable pharmaceutical compositions of dalfampridine |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3687539A4 (en) |
| WO (1) | WO2019058395A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5370879A (en) * | 1990-02-11 | 1994-12-06 | Elan Corporation, Plc | Formulations and their use in the treatment of neurological diseases |
| WO2004082684A1 (en) * | 2003-03-17 | 2004-09-30 | Acorda Therapeutics | Stable oral formulations of aminopyridines and uses thereof |
| RU2536269C1 (en) * | 2013-06-06 | 2014-12-20 | Ооо "Валента-Интеллект" | Composition for treating disturbed innervation (versions) |
| US20170071923A1 (en) * | 2015-09-11 | 2017-03-16 | PharmaDax Inc. | Sustained release oral dosage form containing dalfampridine |
| WO2017058869A1 (en) * | 2015-09-29 | 2017-04-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
-
2018
- 2018-09-21 EP EP18858773.7A patent/EP3687539A4/en not_active Withdrawn
- 2018-09-21 WO PCT/IN2018/050617 patent/WO2019058395A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5370879A (en) * | 1990-02-11 | 1994-12-06 | Elan Corporation, Plc | Formulations and their use in the treatment of neurological diseases |
| WO2004082684A1 (en) * | 2003-03-17 | 2004-09-30 | Acorda Therapeutics | Stable oral formulations of aminopyridines and uses thereof |
| RU2536269C1 (en) * | 2013-06-06 | 2014-12-20 | Ооо "Валента-Интеллект" | Composition for treating disturbed innervation (versions) |
| US20170071923A1 (en) * | 2015-09-11 | 2017-03-16 | PharmaDax Inc. | Sustained release oral dosage form containing dalfampridine |
| WO2017058869A1 (en) * | 2015-09-29 | 2017-04-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP3687539A4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3687539A1 (en) | 2020-08-05 |
| EP3687539A4 (en) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6162196B2 (en) | Delayed sustained drug delivery | |
| CN102046153B (en) | Pharmaceutical compositions comprising brivaracetam | |
| KR101257918B1 (en) | Sustained-release pharmaceutical composition comprising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same | |
| EP2490675B1 (en) | Pharmaceutical compositions of sevelamer | |
| HU231114B1 (en) | Pharmaceutical preparations containing mycophenolic acid or mycophenolate | |
| CN113925833A (en) | Dosage form composition comprising tyrosine protein kinase inhibitor | |
| US20100255099A1 (en) | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders | |
| TW201302198A (en) | Pharmaceutical composition containing nalbuphine and use thereof | |
| US8815288B2 (en) | Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | |
| WO2017153958A1 (en) | Novel polymorphic forms and amorphous form of olaparib | |
| WO2017208136A1 (en) | Pharmaceutical composition of dapagliflozin co-crystal | |
| US20170231969A1 (en) | Pharmaceutical Compositions of Edoxaban | |
| WO2009123169A1 (en) | Amide derivative-containing pharmaceutical composition | |
| EP3687539A1 (en) | Stable pharmaceutical compositions of dalfampridine | |
| EP2929878A1 (en) | Extended release formulations of gabapentin | |
| WO2012129759A1 (en) | Oral dosage formulations containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | |
| KR101048487B1 (en) | Trimebutin Maleic Acid | |
| WO2017037645A1 (en) | Stable pharmaceutical formulations of teriflunomide | |
| EP3911305A1 (en) | A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby | |
| US20120058185A1 (en) | Stable pharmaceutical compositions of olanzapine and process for their preparation | |
| JP2011153135A (en) | Taltirelin preparation and method for maintaining elution properties of taltirelin preparation | |
| EP3173076A1 (en) | A pharmaceutical composition comprising simethicone and otilonium | |
| CN115105478A (en) | Lacosamide pharmaceutical composition, preparation method and application thereof | |
| WO2013054178A2 (en) | Extended release pharmaceutical compositions containing carmabazepine | |
| US20100152269A1 (en) | Modified-release formulations of azabicyclo derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18858773 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2018858773 Country of ref document: EP Effective date: 20200428 |